- Home
- ADGM vs PHGE Comparison
ADGM vs PHGE Comparison
Compare ADGM & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADGM
- PHGE
- Stock Information
- Founded
- ADGM 2011
- PHGE 2015
- Country
- ADGM United States
- PHGE Israel
- Employees
- ADGM N/A
- PHGE N/A
- Industry
- ADGM
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- ADGM
- PHGE Health Care
- Exchange
- ADGM NYSE
- PHGE Nasdaq
- Market Cap
- ADGM 12.7M
- PHGE 13.3M
- IPO Year
- ADGM N/A
- PHGE N/A
- Fundamental
- Price
- ADGM $1.40
- PHGE $0.96
- Analyst Decision
- ADGM
- PHGE Strong Buy
- Analyst Count
- ADGM 0
- PHGE 2
- Target Price
- ADGM N/A
- PHGE $13.50
- AVG Volume (30 Days)
- ADGM 209.5K
- PHGE 48.8K
- Earning Date
- ADGM 03-04-2025
- PHGE 04-02-2025
- Dividend Yield
- ADGM N/A
- PHGE N/A
- EPS Growth
- ADGM N/A
- PHGE N/A
- EPS
- ADGM N/A
- PHGE N/A
- Revenue
- ADGM $543,000.00
- PHGE N/A
- Revenue This Year
- ADGM N/A
- PHGE N/A
- Revenue Next Year
- ADGM N/A
- PHGE N/A
- P/E Ratio
- ADGM N/A
- PHGE N/A
- Revenue Growth
- ADGM 187.30
- PHGE N/A
- 52 Week Low
- ADGM $0.75
- PHGE $0.48
- 52 Week High
- ADGM $9.34
- PHGE $8.55
- Technical
- Relative Strength Index (RSI)
- ADGM N/A
- PHGE 65.22
- Support Level
- ADGM N/A
- PHGE $0.87
- Resistance Level
- ADGM N/A
- PHGE $0.99
- Average True Range (ATR)
- ADGM 0.00
- PHGE 0.08
- MACD
- ADGM 0.00
- PHGE 0.01
- Stochastic Oscillator
- ADGM 0.00
- PHGE 89.20
About ADGM ADAGIO MEDICAL HOLDINGS INC
Adagio Medical Holdings Inc is an innovator in catheter ablation technologies for treatment of cardiac arrhythmias. The company focuses on developing innovative cryoablation technologies that create contiguous, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.